Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses treatments for androgenic manifestations using cyproterone acetate alone or with estrogens, but it does not provide new clinical results.

This study found that combining cyproterone acetate with testosterone enanthate was highly effective in suppressing spermatogenesis, suggesting potential as a reversible male contraceptive method.

Cyproterone Acetate effectively treats androgen-related conditions and is used in prostate cancer therapy and hormone therapy for transgender women.

This review discusses the pharmacological properties and clinical applications of cyproterone acetate and similar antiandrogens, noting previous failures in local applications due to concentration limitations; it reports no new empirical results.

This article reviews the use of cyproterone acetate for conditions like prostate cancer and sexual disorders, highlighting its effects on libido but reporting no new specific trial results.

In this study, cyproterone acetate with ethinyl estradiol effectively treated acne, hirsutism, and alopecia in women, with the highest success in acne and rare side effects similar to estrogen contraceptives.

This study found that cyproterone acetate with ethynyl estradiol improved acne and seborrhea within 3–6 months in women, but had less satisfactory results for alopecia and hirsutism.

In this study, hirsute women treated with cyproterone acetate and ethinyloestradiol experienced significant reductions in sebum secretion and hair growth after several months.

This article reviews the discovery and various physiological effects of cyproterone acetate, reporting its established indications for several androgen-driven conditions but providing no new clinical data.

This study found that some synthesized 17-oximino-5-androsten-3β-yl esters demonstrated stronger cytotoxicity and antiandrogenic activity against prostate cancer cells than finasteride.

In this study, cyproterone acetate combined with estradiol dramatically improved hirsutism symptoms and significantly reduced plasma testosterone and androstenedione levels in patients over periods of up to three years.

In this study, a treatment regimen combining cyproterone acetate and ethinyl estradiol significantly improved acne and seborrhoea in most women after three months, but had varied effects on hirsutism and alopecia.

This review found that adding cyproterone acetate to estradiol showed a subjective improvement in hirsutism versus placebo, but comparisons with other therapies revealed no clinical differences.

This review examines androgen status in male and female obesity and its influence on the metabolic syndrome, but reports no new clinical results.

This study found that parenteral administration of cyproterone acetate was more effective than high-dose oral treatment in reducing facial hair diameter and improving dermatological parameters in patients with severe hirsutism, despite similar androgen suppression.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

This study found that cyproterone acetate treatment improved quality of life and reduced anxiety and depressive symptoms in women with skin manifestations of hyperandrogenism.

This article reviews the effects of antiandrogens on the skin and suggests their potential in treating conditions like acne and hirsutism, but reports no new clinical results.

This study demonstrated that testosterone treatment increases muscle strength and alters body composition in transmen, and the addition of dutasteride does not impair these anabolic effects.

This study found that treatment with cyproterone acetate was generally successful for women with virilizing features, showing improved results in younger women and those with adrenal hirsutism, despite some side effects.

In this study, Tolterodine Tartrate significantly improved symptoms of overactive bladder and showed fewer adverse reactions compared to the control group treatment.

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

This study found that CPA-loaded nanoparticles, particularly SLN formulations, increased CPA epidermal penetration compared to a conventional cream and may reduce side effects in treating androgen-dependent conditions.

In this study, researchers investigated the effects of Aqueous Artocarpus heterophyllus seed extract on testosterone enanthate-induced benign prostatic hyperplasia in adult Wistar rats, using three different dosages to assess its potential as an alternative therapy. Results are not reported in this abstract.